PRESS RELEASES

Peptomyc’s Omomyc-based therapy, OMO-103, has obtained approval for first-in-human phase I/II trial to assess the efficacy and safety of a novel Myc inhibitor

BARCELONA, Spain, March 18, 2021 (GLOBE NEWSWIRE) — Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L. has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound – a disruptive Myc inhibitor, Omomyc (OMO-103).

Building on the proven preclinical efficacy and safety of the Omomyc cell-penetrating peptide (CCP) in mouse models, and Peptomyc’s company’s successful development of anti-Myc peptides for the treatment of several tumor types, this latest milestone represents a greatly anticipated ‘leap’ into the clinical research setting and an important step forward in becoming the first ever clinically viable and direct inhibitor of Myc – a protein implicated in the formation of most tumor types.

Commenting for VHIO’s Global Communications, Laura Soucek, Principal Investigator of VHIO’s Mouse Models of Cancer Therapies and an ICREA Research Professor said, “MYC has been considered an ‘undruggable’ cancer target for many years. We have previously shown that Myc blockade has an excellent therapeutic effect in several mouse models, with mild side effects that are well tolerated and reversible. Now that we have received approval to initiate our early phase clinical trial, we can further progress in testing the safety and efficacy of our Omomyc-based therapy for the benefit of those who matter the most – our patients.”

Over the last 20 years Laura’s determined research efforts have centered on proving countless cynics wrong in her ambitions to combat resistance to therapy and cancer regression through clinically inhibiting the Myc oncogene. Found deregulated in most, if not all tumor types, and as a key driver of cancer progression and maintenance, Myc is consequently a major contender as a cancer target and yet, its promise has not yet been successfully translated into benefits at the patient level.

“At the preclinical level, we have reported the efficacy of Omomyc as a cell penetrating peptide – essentially, a mini-protein with the ability to enter cells and reach its target compartment, namely, the nucleus. The successful intravenous systemic administration of our mini-protein MYC inhibitor against lung cancer and other malignancies, has led to this week’s exciting development,” said Marie-Eve Beaulieu, Peptomyc’s Chief Scientific Officer.

She added, “Our strategy differs immensely from other previous approaches aimed at inhibiting Myc. Our Omomyc mini-protein is large enough to accurately fold and adapt to Myc’s disordered structure, which determines the specificity of inhibition. At the same time, it is small enough to penetrate tumor cells and nuclei in order to reach its target. By conducting our first-in-human early phase clinical trial, we hope to drive this novel therapy into the clinic for the more effective treatment of multiple tumor types”.

Twenty patients with advanced solid tumors across various cancer types, whose disease has progressed after previous treatments, will be enrolled in the Phase I study. This clinical trial will be carried out at three different Spanish sites: our Vall d’Hebron University Hospital (HUVH), also located within the Vall d’Hebron Barcelona Hospital Campus, the HM Sanchinarro University Hospital, and the Fundación Jiménez Díaz University Hospital (Madrid).

VHIO’s Elena Garralda, Director of our Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa” Foundation, and Head of Early Clinical Drug Development at our Institute, is the Principal Investigator of Peptomyc’s clinical study at Vall d’Hebron. She noted, “I am honored and privileged to participate in this study of a VHIO-developed molecule. Since Myc has traditionally been considered as an impossible drug target, this clinical trial represents a pivotal development. Confirmation of OMO-103’s safety and efficacy in patients would be extremely important for the future treatment of cancer”.

“To get to where we are today has been a long and challenging journey. While we have had to overcome many obstacles, we have successfully proven our hypothesis about Myc by achieving amazing results in animal models. We very much hope that Omomyc will meet the same expectations in clinical research lso that we can ultimately provide new hope for cancer patients, particularly for those suffering from advanced disease,” concluded Laura Soucek.

PEPTOMYC S.L.
Office email: [email protected]
Centre CELLEX - C/ Natzaret, 115-117 - Barcelona, Spain, 08035

Latest News

Conagen’s Novel Solution to Making Natural Capsaicin by Fermentation Accessible

Bedford, Mass., April 22, 2021 (GLOBE NEWSWIRE) — Scalable, sustainable capsaicin ingredients for its use in food, consumer and industrial products have now become more accessible. Conagen announced it has successfully scaled-up its fermentation process for the production of premium capsaicin and its related capsaicinoid molecules. Chili peppers are widely used as a food additive in spicy […]

Global Pandemic Fueled Renewed Investor Interest in Silver in 2020

Record Silver-Backed Exchange-Traded Product Inflows Drove Global Holdings to Over One Billion Ounces; Coin and Bar Demand Rose to a Four-Year High WASHINGTON, April 22, 2021 (GLOBE NEWSWIRE) — Considerable growth in silver investment was the chief driver of the metal’s 27 percent average price gain in 2020. Leading the way was substantial demand for […]

โรงงานใหม่ของ Nikkiso Cryo Inc. เพิ่มการผลิตปั๊มไครโอเจนิค

ลาสเวกัส, April 22, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryo Inc. (NCI) ในเมืองลาสเวกัส รัฐเนวาดา ซึ่งเป็นสมาชิกของ Nikkiso Clean Energy and Industrial Gases Group (กลุ่ม) และเป็นส่วนหนึ่งของ Nikkiso Co., Ltd (ญี่ปุ่น) ได้ประกาศเกี่ยวกับโรงงานใหม่ซึ่งจะเพิ่มประสิทธิภาพและขีดความสามารถในการผลิตปั๊มไครโอเจนิค โรงงานใหม่ที่ใหญ่ขึ้นของ NCI เป็นสิ่งจำเป็นเนื่องจากการเติบโตและความต้องการผลิตภัณฑ์และบริการปั๊มไครโอจีนิคอย่างต่อเนื่องของตลาด LNG ทั่วโลก (หลักๆ คือสถานีส่งออกและนำเข้า LNG) โรงงานสำนักงานขนาด 15,000 ตารางฟุตอยู่ใกล้กับสถานที่ทดสอบการผลิตหลัก ซึ่งมีการปรับปรุงประสิทธิภาพในการดำเนินงาน ความปลอดภัย และขีดความสามารถในการผลิตที่เพิ่มขึ้นอย่างมาก ในจำนวนนี้ยังมีระบบหอเผาทิ้งระดับพื้นดินใหม่ที่มีประสิทธิภาพและขีดความสามารถในการผลิตที่ดีขึ้น อีกทั้งยังมีการติดตั้งเครนโอเวอร์เฮดไฟฟ้าประเภทที่ 1 แบบที่ 1 บนแผงทดสอบ ซึ่งช่วยลดต้นทุนและเพิ่มผลผลิตโดยช่วยให้สามารถทำงานหลายอย่างในเวลาเดียวกัน เพิ่มความปลอดภัยโดยอนุญาตให้สามารถยกและติดตั้งปั๊มหลายตัวสำหรับการทดสอบ รวมถึงได้รับการรับรองสำหรับพื้นที่อันตราย “นี่เป็นก้าวต่อไปที่น่าตื่นเต้นสำหรับบริษัทของเราและเป็นประโยชน์อย่างมากสำหรับลูกค้าของเรา NCI จะสามารถเพิ่มผลผลิตและลดเวลาในการผลิตได้” Daryl […]

AB InBev 100+ Accelerator partners with The Coca-Cola Company, Colgate-Palmolive and Unilever for Sustainable Startup Innovation

NEW YORK, April 22, 2021 (GLOBE NEWSWIRE) — Today, The Coca-Cola Company, Colgate-Palmolive Company and Unilever have joined the Anheuser-Busch InBev (AB InBev) 100+ Accelerator to fund and pilot sustainable innovation in supply chains. Launched in 2018, the 100+ Accelerator is a global incubator program that works to solve supply chain challenges across water stewardship, […]